Answers are grounded in this paper and cite their sources.
Background: Point-of-care (POC) gonorrhea and chlamydia (GC/CT) testing may reduce unnecessary antibiotic use but optimal integration into high throughput clinical settings remains unclear. Methods: The municipal Sexual Health Clinic (SHC) in Seattle, Washington routinely uses laboratory-based GC/CT testing. In April 2025, the SHC added a POC test (binx io ), which provides results in <30 minutes for male urine and female vaginal swabs. We conducted a mixed-methods evaluation (explanatory sequential design [QUAN->QUAL]) of the first 10 months of implementation. We abstracted quantitative data (e.g., demographics, symptoms) from the clinic’s electronic medical record. We collected qualitative data via in-depth interviews with six purposively sampled SHC clinic staff. Results: Between April-October, 2025 there were 2,618 clinic visits at the SHC that included GC/CT urine or vaginal testing. POC testing comprised 5.5% (n=97) of urine tests and 4.9% (n=41) of vaginal tests. Compared to laboratory testing, POC vaginal testing occurred more often among patients reporting urogenital symptoms (75.6% vs. 44.8%), abdominal pain (24.4% vs. 12.2%), and being a contact to CT (7.3% vs. 1.5%). We did not observe these differences for urine testing. Clinic staff interviews revealed three themes: (1) POC testing is feasible to integrate in a high-volume SHC; (2) its perceived value-add is generally high but varies by patient characteristics; (3) time is the main implementation barrier but facilitators and barriers likely differ across settings. Conclusions: POC testing was infrequently used in this setting but was feasible to integrate and a useful complement to laboratory-based testing in certain scenarios.
No takes yet. Share an insight, caveat, or question.
Khosropour et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: